Bicipital Tendonitis, DeQuervain's Tenosynovitis of the Wrist, Lateral Epicondylitis of the Elbow, Medial Epicondylitis of the Elbow, Rotator Cuff Tendonitis, Subacromial Bursitis of the Shoulder, Subdeltoid Bursitis of the Shoulder
Conditions
Keywords
Tendonitis, Bursitis
Brief summary
The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be one of the following: the affected shoulder, elbow, or wrist. The secondary purpose of this study is to assess the safety and tolerability of the diclofenac patch on the subject's skin, in the location being studied.
Detailed description
Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.
Interventions
DRUGdiclofenac sodium
15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
DRUGMatching Placebo
Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Sponsors
PPD Development, LP
Cerimon Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 years to 75 years of age * Onset of painful upper extremity tendonitis or bursitis, no more than 21 days prior to study entry * Eligible diagnoses are rotator cuff tendonitis, bicipital tendonitis or subdeltoid/subacromial bursitis of the shoulder, medial or lateral epicondylitis of the elbow, and DeQuervain's tenosynovitis of the wrist * Spontaneous pain with motion or resisted motion and tenderness to palpation over the involved tendon(s), bursa, or epicondyle * Presence of pain of at least 5, with a maximum of 9, on an 11-point Numerical Rating Scale (NRS)
Exclusion criteria
* Aspirin, or short half-life NSAID use within 12 hours, or longer half-life NSAID use within 24 hours prior to study entry (see Appendix B: for table of NSAIDs) * Opioid use within 3 days prior to study entry * Topical treatment, other than local ice or heat, applied to the painful region within 3 days prior to study entry * History of peptic ulcer disease within 1 year prior to study entry, any history of gastrointestinal bleeding, or coagulation disorder * A history of, or evidence for underlying articular disease such as osteoarthritis, rheumatoid arthritis, gout, or pseudogout (calcium pyrophosphate deposition disease) * Clinically significant and poorly controlled pulmonary, gastrointestinal, hepatic, renal, endocrine, or cardiovascular disease * A history of hypersensitivity to diclofenac or diclofenac-containing products * A history of intolerance to acetaminophen (rescue medication in this trial) * A history of skin sensitivity to adhesives (e.g. adhesive tape) * Pregnant or breastfeeding women and women of child-bearing potential not using effective means of contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the efficacy of diclofenac in subjects with tendonitis or bursitis of the shoulder, elbow, or wrist. | 14 days |
Secondary
| Measure | Time frame |
|---|---|
| Assess the safety and tolerability of diclofenac in subjects with tendonitis or bursitis of the shoulder, elbow, or wrist. | 14 days |
Countries
United States
Outcome results
None listed